Green Thumb Ended Its String of Profitable Quarters. Is the Stock a Buy?

TRLV posted its first quarterly loss since Q2 2025, snapping a four-quarter profitable streak, even as revenue climbed 11.3% year over year to $324.4 million.

The source attributes the loss to expansion spending, including the opening of six new RISE dispensaries. That framing matters: the red bottom line traces to new-store buildout rather than a revenue stumble. Top-line growth at double-digit pace is hard to square with a demand problem.

Cash generation held up. TRLV produced $58 million in operating cash flow, and management kept buying back stock, retiring 13.4 million shares. Repurchasing that volume in a loss quarter signals the company views the weakness as temporary, though that is interpretation, not a stated management claim.

Forward catalysts center on legalization in Virginia and expansion opportunities in key states. The bull case rests on new dispensaries maturing into earnings contributors once the openings stop weighing on results.